Background:
- Lung cancer is the leading cause of cancer-related deaths worldwide, and >50% of patients present as stage III or IV.
- Recently, patients with relapsing/remitting stage III NSCLC (R/R) were described to have worse overall survival compared to de novo stage IV (DN) patients when treated with chemoradiation and immunotherapy.
- In this study, we aimed to compare the molecular and immune landscapes of these two patient populations to identify potential differences in biomarkers of resistance and possible targets for therapy.